Kennedy Capital Management, Inc. Immuno Gen, Inc. Transaction History

Kennedy Capital Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $3 Million - $7.22 Million	241,032 New	241,032 $7.15 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $1.02 Million - $1.36 Million	-277,210 Reduced 58.09%	200,032 $768,000
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $1,897 - $2,631	-417 Reduced 0.09%	477,242 $2.37 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $1.6 Million - $2.31 Million	356,952 Added 295.72%	477,659 $2.28 Million
Q2 2022 Aug 10, 2022	BUY	$3.15 - $5.76 $380,227 - $695,272	120,707 New	120,707 $543,000

Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $1.17 Million - $1.89 Million	-179,242 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$3.7 - $7.66 $3.97 Million - $8.21 Million	-1,072,216 Reduced 85.68%	179,242 $1.16 Million
Q3 2020 Nov 16, 2020	BUY	$3.45 - $4.89 $4.32 Million - $6.12 Million	1,251,458 New	1,251,458 $4.51 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Kennedy Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kennedy Capital Management, Inc. with notifications on news.